% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Lauer:300305,
      author       = {U. M. Lauer$^*$ and A. Awada and S. Postel-Vinay and G. I.
                      Shapiro and C. Thieblemont and S. A. Piha-Paul and P. K.
                      Paik and D. R. Shepard and L. I. Docampo and R. Galot and S.
                      Rottey and B. Sadrolhefazi and K. Marzin and H. Musa and P.
                      Schöffski},
      title        = {{F}inal results from the phase {I}a/{I}b study of the novel
                      bromodomain and extra-terminal domain inhibitor, {BI}
                      894999, in patients with advanced solid tumors or diffuse
                      large {B}-cell lymphoma.},
      journal      = {ESMO open},
      volume       = {10},
      number       = {5},
      issn         = {2059-7029},
      address      = {[London]},
      publisher    = {Elsevier},
      reportid     = {DKFZ-2025-00755},
      pages        = {104499},
      year         = {2025},
      abstract     = {Bromodomain and extraterminal domain (BET) inhibitors have
                      demonstrated efficacy in solid and hematological
                      malignancies. BI 894999, a novel, orally administered BET
                      inhibitor, has demonstrated preclinical efficacy.This was an
                      open-label, dose-finding study evaluating BI 894999 for
                      diffuse large B-cell lymphoma (DLBCL; phase Ia extension)
                      and solid tumors [colorectal cancer (CRC), nuclear protein
                      in testis (NUT) carcinoma, metastatic castration-resistant
                      prostate cancer (mCRPC) and small-cell lung cancer (SCLC);
                      phase Ib cohort]. The primary endpoint was dose-limiting
                      toxicities (DLTs) during the maximum tolerated dose (MTD)
                      period (phase Ia) and treatment period (phase Ib).Eighteen
                      patients with DLBCL were enrolled in the phase Ia extension
                      and 79 with solid tumors in phase Ib cohorts (SCLC, n = 12;
                      CRC, n = 14; mCRPC, n = 11; NUT carcinoma, n = 42). Four
                      patients had DLTs in phase Ia and 17 in phase Ib; the most
                      frequent was grade 4 thrombocytopenia. The MTD for DLBCL was
                      1.5 mg (days 1-14/21). One patient $(5.6\%)$ with DLBCL
                      achieved a partial response (PR) and three $(16.7\%)$ had
                      stable disease. Of 42 patients with NUT carcinoma, 3
                      patients $(7.1\%)$ had responses (complete response, n = 1;
                      confirmed PR, n = 1; unconfirmed PR, n = 1). Responses in
                      other solid tumor types (n = 37) included one patient
                      $(2.7\%)$ with mCRPC who had a confirmed PR.The safety
                      profile of BI 894999 was consistent with those of other BET
                      inhibitors. Due to minimal efficacy results, further
                      evaluation of BI 894999 as monotherapy is not planned.},
      keywords     = {bromodomain and extraterminal domain inhibitor (Other) /
                      diffuse large B-cell lymphoma (Other) / dose escalation
                      (Other) / dose-limiting toxicities (Other) / solid tumor
                      (Other)},
      cin          = {TU01},
      ddc          = {610},
      cid          = {I:(DE-He78)TU01-20160331},
      pnm          = {899 - ohne Topic (POF4-899)},
      pid          = {G:(DE-HGF)POF4-899},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:40203516},
      doi          = {10.1016/j.esmoop.2025.104499},
      url          = {https://inrepo02.dkfz.de/record/300305},
}